EEG and behavioral aspects of the interaction of anticholinergic hallucinogens with centrally active compounds.
D000166:Acridines / Q000494:pharmacology; D000293:Adolescent; D000328:Adult; D001285:Atropine / Q000494:pharmacology*; D001519:Behavior / Q000187:drug effects*; D002746:Chlorpromazine / Q000494:pharmacology; D003243:Consciousness / Q000187:drug effects; D003913:Dextroamphetamine / Q000494:pharmacology; D004569:Electroencephalography; D005260:Female; D006213:Hallucinogens / Q000494:pharmacology*; D006801:Humans; D007099:Imipramine / Q000494:pharmacology; D008238:Lysergic Acid Diethylamide / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects; D009388:Neostigmine / Q000494:pharmacology; D010276:Parasympatholytics / Q000494:pharmacology*; D014474:Unconsciousness / Q000139:chemically induced; D015016:Yohimbine / Q000494:pharmacology
D000166:Acridines; D006213:Hallucinogens; D010276:Parasympatholytics; D015016:Yohimbine; D009388:Neostigmine; D001285:Atropine; D008238:Lysergic Acid Diethylamide; D007099:Imipramine; D003913:Dextroamphetamine; D002746:Chlorpromazine